There are however also drawbacks in using cobalt-based compounds such as their high cost and their low thermostability. Manganese has similar advantages and a lower cost, however there are some problems associated with using manganese. The main problem is that manganese tends to dissolve into the electrolyte over time. For this reason cobalt is still the most common element which is used in the lithium compounds. There is much research being done into finding new materials which can be used to create cheaper and longer lasting Li-ion batteries

Anodes
The anodes used in mass-produced Li-ion batteries are either carbon based (usually graphite) or made out of spinel lithium titanate (Li4Ti5O12). Graphite anodes have been successfully implemented in many modern commercially available batteries due to its cheap price, longevity and high energy density. However, it presents issues of dendrite growth, with risks of shorting the battery and posing a safety issue. Li4Ti5O12 has the second largest market share of anodes, due to its stability and good rate capability, but with challenges such as low capacity. During the early 2000, Silicon anode research began picking up pace, becoming one of the 2020s most promising candidates for future Lithium ion battery anodes. Silicon has one of the highest gravimetric capacities when compared to graphite and  Li4Ti5O12 as well as a high volumetric one . Furthermore, Silicon has the advantage of operating under a reasonable open circuit voltage without parasitic lithium reactions. However, Silicon anodes have a major issue of volumetric expansion during lithiation of around 360%.
If a person has a QTcF of > 500 ms or a significant ventricular arrythmia, bedaquiline and other QT prolonging drugs should be stopped.There is considerable controversy over the approval for the drug, as one of the largest studies to date had more deaths in the group receiving bedaquiline that those receiving placebo. Ten deaths occurred in the bedaquiline group out of 79, while two occurred in the placebo group, out of 81. Of the 10 deaths on bedaquiline, one was due to a motor vehicle accident, five were judged as due to progression of the underlying tuberculosis and three were well after the person had stopped receiving bedaquiline. However, there is still significant concern for the higher mortality in people treated with bedaquiline, leading to the recommendation to limit its use to situations where a four drug regimen cannot otherwise be constructed, limit use with other medications that prolong the QT interval, and the placement of a prominent black box warning. Drug interactions
Bedaquiline should not be co-administered with other drugs that are strong inducers or inhibitors of CYP3A4, the liver enzyme responsible for oxidative metabolism of the drug. Co-administration with rifampin, a strong CYP3A4 inducer, results in a 52% decrease in the AUC of the drug. This reduces the exposure of the body to the drug and decreases the antibacterial effect.